RCKT
Rocket Pharmaceuticals, Inc.$3.39-0.04 (-1.17%)Prev Close$3.43·MCap$365.8M·P/E—·Vol3.15M·Yield—
▲
Buys (12M)
1
$34.4K
▼
Sells (12M)
26
$978.6K
◆
Net Activity
Net Seller
$944.2K
●
Active Insiders
7
last 12 mo
Over the past 12 months, insider activity at Rocket Pharmaceuticals, Inc. (RCKT) has been dominated by selling, with 1 insider purchase totaling $34.4K and 26 insider sales totaling $978.6K. The most recent insider transaction was by Wilson Martin (officer: General Counsel), who sold $256.5K worth of shares on Sep 15, 2026. Rocket Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $365.8M.
RCKT Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Wilson Martin | officer: General Counsel | Sell | 75,364 | $3.40 | $256.5K | 598,489 |
| Aug 20, 2026 | Wilson Martin | officer: General Counsel | Sell | 631 | $3.38 | $2.1K | 673,853 |
| Aug 20, 2026 | Shah Gaurav | officer: CEO | Sell | 2,293 | $3.38 | $7.8K | 1,056,594 |
| Aug 17, 2026 | Wilson Martin | officer: General Counsel | Sell | 3,493 | $3.38 | $11.8K | 674,484 |
| Aug 17, 2026 | Shah Gaurav | officer: CEO | Sell | 2,837 | $3.38 | $9.6K | 1,058,887 |
| Aug 13, 2026 | Stevens Christopher James | officer: Chief Operating Officer | Sell | 36,658 | $3.50 | $128.3K | 505,784 |
| Aug 13, 2026 | Chaudhuri Sarbani | officer: See Remarks | Sell | 4,701 | $3.50 | $16.4K | 262,809 |
| May 26, 2026 | Shah Gaurav | officer: CEO | Sell | 55,684 | $3.09 | $171.8K | 1,061,724 |
| May 21, 2026 | Wilson Martin | officer: General Counsel | Sell | 662 | $3.01 | $2.0K | 677,977 |
| May 21, 2026 | Militello John | officer: See Remarks | Sell | 384 | $3.01 | $1.2K | 89,780 |
| May 21, 2026 | Shah Gaurav | officer: CEO | Sell | 2,409 | $3.01 | $7.3K | 1,040,918 |
| May 14, 2026 | Shah Gaurav | officer: CEO | Sell | 2,728 | $3.61 | $9.8K | 1,043,327 |
| May 14, 2026 | Wilson Martin | officer: General Counsel | Sell | 3,361 | $3.61 | $12.1K | 678,639 |
| May 14, 2026 | Militello John | officer: See Remarks | Sell | 855 | $3.61 | $3.1K | 90,164 |
| May 11, 2026 | Chaudhuri Sarbani | officer: See Remarks | Sell | 17,650 | $3.84 | $67.7K | 267,510 |
| Feb 20, 2026 | Militello John | officer: See Remarks | Sell | 1,157 | $3.34 | $3.9K | 91,019 |
| Feb 20, 2026 | Shah Gaurav | officer: CEO | Sell | 5,990 | $3.34 | $20.0K | 1,046,055 |
| Feb 20, 2026 | Wilson Martin | officer: General Counsel | Sell | 1,376 | $3.34 | $4.6K | 682,000 |
| Feb 18, 2026 | Militello John | officer: See Remarks | Sell | 3,726 | $3.31 | $12.3K | 92,176 |
| Feb 18, 2026 | Shah Gaurav | officer: CEO | Sell | 12,279 | $3.31 | $40.7K | 1,052,045 |
| Feb 18, 2026 | Wilson Martin | officer: General Counsel | Sell | 12,253 | $3.31 | $40.6K | 683,376 |
| Jan 2, 2026 | Bjork Elisabeth | Director | Buy | 10,000 | $3.44 | $34.4K | 0 |
| Nov 18, 2025 | Militello John | See Remarks | Sell | 1,086 | $2.98 | $3.2K | 0 |
| Nov 18, 2025 | Schwartz Jonathan David | See Remarks | Sell | 2,545 | $2.98 | $7.6K | 0 |
| Nov 18, 2025 | Shah Gaurav | CEO | Sell | 6,276 | $2.98 | $18.7K | 0 |
| Nov 18, 2025 | Wilson Martin | General Counsel | Sell | 1,646 | $2.98 | $4.9K | 0 |
| Oct 14, 2025 | Militello John | See Remarks | Sell | 28,918 | $3.96 | $114.6K | 0 |
| Aug 27, 2025 | Bjork Elisabeth | Director | Buy | 10,000 | $3.41 | $34.1K | 0 |
| Aug 18, 2025 | Militello John | See Remarks | Sell | 1,060 | $3.04 | $3.2K | 0 |
| Aug 18, 2025 | Schwartz Jonathan David | See Remarks | Sell | 2,485 | $3.04 | $7.6K | 0 |
| Aug 18, 2025 | Shah Gaurav | CEO | Sell | 2,234 | $3.05 | $6.8K | 0 |
| Aug 18, 2025 | Wilson Martin | General Counsel | Sell | 1,592 | $3.04 | $4.8K | 0 |
| Jul 3, 2025 | Ondrey Aaron | Chief Financial Officer | Sell | 1,477 | $2.88 | $4.3K | 0 |
| May 20, 2025 | Militello John | See Remarks | Sell | 357 | $6.45 | $2.3K | 0 |
| May 20, 2025 | Patel Kinnari | See Remarks | Sell | 767 | $6.45 | $4.9K | 0 |
| May 20, 2025 | Schwartz Jonathan David | See Remarks | Sell | 801 | $6.45 | $5.2K | 0 |
| May 20, 2025 | Shah Gaurav | CEO | Sell | 2,253 | $6.45 | $14.5K | 0 |
| May 20, 2025 | Wilson Martin | General Counsel | Sell | 587 | $6.45 | $3.8K | 0 |
| May 16, 2025 | Militello John | See Remarks | Sell | 655 | $6.53 | $4.3K | 0 |
| May 16, 2025 | Wilson Martin | General Counsel | Sell | 946 | $6.53 | $6.2K | 0 |
| Apr 22, 2025 | Militello John | See Remarks | Sell | 718 | $7.16 | $5.1K | 0 |
| Apr 10, 2025 | Shah Gaurav | CEO | Buy | 20,000 | $5.08 | $101.6K | 0 |
| Apr 9, 2025 | Patel Kinnari | See Remarks | Buy | 21,099 | $4.70 | $99.2K | 0 |
| Apr 4, 2025 | Ondrey Aaron | Chief Financial Officer | Sell | 7,489 | $5.29 | $39.6K | 0 |
| May 17, 2024 | Schwartz Jonathan David | See Remarks | Sell | 15,093 | $14.84 | $224.0K | 0 |
| Apr 1, 2022 | Schwartz Jonathan David | See Remarks | Sell | 45,000 | $16.41 | $738.7K | 213,967 |
| Feb 8, 2022 | Shah Gaurav | CEO | Buy | 22,000 | $17.34 | $381.5K | 517,639 |
| Jun 21, 2021 | Makker Gotham | Sell | 35,085 | $46.85 | $1.64M | 1,296,801 | |
| May 13, 2021 | RTW INVESTMENTS, LP | Director | Sell | 725,000 | $40.03 | $29.02M0.7% OS | 15,460,119 |
RCKT Insider Buying Activity
The following table shows recent insider purchases of Rocket Pharmaceuticals, Inc. (RCKT) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | Bjork Elisabeth | Director | Buy | 10,000 | $3.44 | $34.4K | 0 |
| Aug 27, 2025 | Bjork Elisabeth | Director | Buy | 10,000 | $3.41 | $34.1K | 0 |
| Apr 10, 2025 | Shah Gaurav | CEO | Buy | 20,000 | $5.08 | $101.6K | 0 |
| Apr 9, 2025 | Patel Kinnari | See Remarks | Buy | 21,099 | $4.70 | $99.2K | 0 |
| Feb 8, 2022 | Shah Gaurav | CEO | Buy | 22,000 | $17.34 | $381.5K | 517,639 |
RCKT Insider Selling Activity
The following table shows recent insider sales of Rocket Pharmaceuticals, Inc. (RCKT) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Wilson Martin | officer: General Counsel | Sell | 75,364 | $3.40 | $256.5K | 598,489 |
| Aug 20, 2026 | Wilson Martin | officer: General Counsel | Sell | 631 | $3.38 | $2.1K | 673,853 |
| Aug 20, 2026 | Shah Gaurav | officer: CEO | Sell | 2,293 | $3.38 | $7.8K | 1,056,594 |
| Aug 17, 2026 | Wilson Martin | officer: General Counsel | Sell | 3,493 | $3.38 | $11.8K | 674,484 |
| Aug 17, 2026 | Shah Gaurav | officer: CEO | Sell | 2,837 | $3.38 | $9.6K | 1,058,887 |
| Aug 13, 2026 | Stevens Christopher James | officer: Chief Operating Officer | Sell | 36,658 | $3.50 | $128.3K | 505,784 |
| Aug 13, 2026 | Chaudhuri Sarbani | officer: See Remarks | Sell | 4,701 | $3.50 | $16.4K | 262,809 |
| May 26, 2026 | Shah Gaurav | officer: CEO | Sell | 55,684 | $3.09 | $171.8K | 1,061,724 |
| May 21, 2026 | Wilson Martin | officer: General Counsel | Sell | 662 | $3.01 | $2.0K | 677,977 |
| May 21, 2026 | Militello John | officer: See Remarks | Sell | 384 | $3.01 | $1.2K | 89,780 |
| May 21, 2026 | Shah Gaurav | officer: CEO | Sell | 2,409 | $3.01 | $7.3K | 1,040,918 |
| May 14, 2026 | Shah Gaurav | officer: CEO | Sell | 2,728 | $3.61 | $9.8K | 1,043,327 |
| May 14, 2026 | Wilson Martin | officer: General Counsel | Sell | 3,361 | $3.61 | $12.1K | 678,639 |
| May 14, 2026 | Militello John | officer: See Remarks | Sell | 855 | $3.61 | $3.1K | 90,164 |
| May 11, 2026 | Chaudhuri Sarbani | officer: See Remarks | Sell | 17,650 | $3.84 | $67.7K | 267,510 |
| Feb 20, 2026 | Militello John | officer: See Remarks | Sell | 1,157 | $3.34 | $3.9K | 91,019 |
| Feb 20, 2026 | Shah Gaurav | officer: CEO | Sell | 5,990 | $3.34 | $20.0K | 1,046,055 |
| Feb 20, 2026 | Wilson Martin | officer: General Counsel | Sell | 1,376 | $3.34 | $4.6K | 682,000 |
| Feb 18, 2026 | Militello John | officer: See Remarks | Sell | 3,726 | $3.31 | $12.3K | 92,176 |
| Feb 18, 2026 | Shah Gaurav | officer: CEO | Sell | 12,279 | $3.31 | $40.7K | 1,052,045 |
| Feb 18, 2026 | Wilson Martin | officer: General Counsel | Sell | 12,253 | $3.31 | $40.6K | 683,376 |
| Nov 18, 2025 | Militello John | See Remarks | Sell | 1,086 | $2.98 | $3.2K | 0 |
| Nov 18, 2025 | Schwartz Jonathan David | See Remarks | Sell | 2,545 | $2.98 | $7.6K | 0 |
| Nov 18, 2025 | Shah Gaurav | CEO | Sell | 6,276 | $2.98 | $18.7K | 0 |
| Nov 18, 2025 | Wilson Martin | General Counsel | Sell | 1,646 | $2.98 | $4.9K | 0 |
| Oct 14, 2025 | Militello John | See Remarks | Sell | 28,918 | $3.96 | $114.6K | 0 |
| Aug 18, 2025 | Militello John | See Remarks | Sell | 1,060 | $3.04 | $3.2K | 0 |
| Aug 18, 2025 | Schwartz Jonathan David | See Remarks | Sell | 2,485 | $3.04 | $7.6K | 0 |
| Aug 18, 2025 | Shah Gaurav | CEO | Sell | 2,234 | $3.05 | $6.8K | 0 |
| Aug 18, 2025 | Wilson Martin | General Counsel | Sell | 1,592 | $3.04 | $4.8K | 0 |
| Jul 3, 2025 | Ondrey Aaron | Chief Financial Officer | Sell | 1,477 | $2.88 | $4.3K | 0 |
| May 20, 2025 | Militello John | See Remarks | Sell | 357 | $6.45 | $2.3K | 0 |
| May 20, 2025 | Patel Kinnari | See Remarks | Sell | 767 | $6.45 | $4.9K | 0 |
| May 20, 2025 | Schwartz Jonathan David | See Remarks | Sell | 801 | $6.45 | $5.2K | 0 |
| May 20, 2025 | Shah Gaurav | CEO | Sell | 2,253 | $6.45 | $14.5K | 0 |
| May 20, 2025 | Wilson Martin | General Counsel | Sell | 587 | $6.45 | $3.8K | 0 |
| May 16, 2025 | Militello John | See Remarks | Sell | 655 | $6.53 | $4.3K | 0 |
| May 16, 2025 | Wilson Martin | General Counsel | Sell | 946 | $6.53 | $6.2K | 0 |
| Apr 22, 2025 | Militello John | See Remarks | Sell | 718 | $7.16 | $5.1K | 0 |
| Apr 4, 2025 | Ondrey Aaron | Chief Financial Officer | Sell | 7,489 | $5.29 | $39.6K | 0 |
| May 17, 2024 | Schwartz Jonathan David | See Remarks | Sell | 15,093 | $14.84 | $224.0K | 0 |
| Apr 1, 2022 | Schwartz Jonathan David | See Remarks | Sell | 45,000 | $16.41 | $738.7K | 213,967 |
| Jun 21, 2021 | Makker Gotham | Sell | 35,085 | $46.85 | $1.64M | 1,296,801 | |
| May 13, 2021 | RTW INVESTMENTS, LP | Director | Sell | 725,000 | $40.03 | $29.02M0.7% OS | 15,460,119 |
RCKT Insiders
Similar Stocks to RCKT
VRTX
Vertex Pharmaceuticals Incorporated
$513.52-1.17%
$132.26B
REGN
Regeneron Pharmaceuticals, Inc.
$772.87-2.63%
$83.21B
MRNA
Moderna, Inc.
$142.93-2.49%
$57.13B
RVMD
Revolution Medicines, Inc.
$204.47-0.31%
$44.15B
INSM
Insmed Incorporated
$119.56-4.63%
$28.05B
INCY
Incyte Corporation
$121.65-0.43%
$24.62B
UTHR
United Therapeutics Corporation
$500.44-0.42%
$21.10B
NBIX
Neurocrine Biosciences, Inc.
$150.44-4.31%
$15.71B